Novara Biotech reports quarterly revenue above the internal plan
Novara Biotech said demand in its Biotechnology segment held up through the quarter, with management reiterating full-year margin guidance.
Sector Desk
Novara Biotech
Healthcare · Biotechnology
Updated UTC
US$ 410,77
+5,46+1,35%
After hoursUS$ 412,82+0,50%
| Item | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| Revenue | 31,67 bi | 37,26 bi | 41,96 bi | 48,31 bi | 53,67 bi |
| Gross profit | 18,76 bi | 21,53 bi | 23,9 bi | 26,46 bi | 32,34 bi |
| Operating income | 6,26 bi | 7,62 bi | 7,85 bi | 9,58 bi | 11,72 bi |
| Net income | 4,88 bi | 5,63 bi | 6,17 bi | 5,78 bi | 7,65 bi |
Clinical-stage developer of oral therapies for autoimmune and metabolic disorders.
Novara Biotech said demand in its Biotechnology segment held up through the quarter, with management reiterating full-year margin guidance.
Sector Desk
The company approved a multi-year capital program intended to shorten lead times for its largest customers.
Sector Desk
A sell-side desk kept a neutral rating while noting that near-term estimates already reflect steady execution.
Sector Desk
The board named an internal candidate with prior treasury and investor-relations experience to the role.
Sector Desk
The authorization covers a modest slice of the float and will be funded from operating cash flow.
Terminal Brief